Retigabine
Retigabine is a positive allosteric modulator of KCNQ2-5 (KV7.2-7.5) ion channels, with EC50 values being 1.4, 1.6 and 5.2 μM for KCNQ3/5, KCNQ2/3 and KCNQ4, respectively. Retigabine is the first neuronal potassium channel opener used for the treatment of epilepsy. KCNQ2-5 channels, predominantly expressed in neurons, are important determinants of cellular excitability. The occurrence of human genetic mutations in KCNQ2/3 channels are associated with the syndrome of benign familial neonatal convulsions.?
References:
1.Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia, 2012, 53(3): 412-424.
2.Stas JI, Bocksteins E, Jensen CS, et al. The anticonvulsant retigabine suppresses neuronal KV2-mediated currents. Scientific Reports, 2016, 6: 35080.
3. De Sarro G, Di Paola ED, Conte G, et al. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363(3): 330-336.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 303.33 |
| Cas No. | 150812-12-7 |
| Formula | C16H18FN3O2 |
| Solubility | insoluble in H2O; ≥11.1 mg/mL in EtOH with ultrasonic; ≥12.95 mg/mL in DMSO |
| Chemical Name | (E)-ethyl hydrogen (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbonimidate |
| SDF | Download SDF |
| Canonical SMILES | CCO/C(O)=N/C1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[2] | |
|
Cell lines |
HEK293 cells transfected with KV2.1 |
|
Reaction Conditions |
0.1, 0.3, 1 or 3?μM retigabine for 4 h incubation |
|
Applications |
Retigabine reduced the KV2.1 current density in a concentration-dependent manner. The current density was significantly reduced by approximately 2.5-fold after exposure to 1 and 3 μM retigabine. Thus, KV2.1 was identified as a new molecular target for retigabine, with the potential to further explain retigabine's neuroprotective properties. |
| Animal experiment:[3] | |
|
Animal models |
DBA/2 mice |
|
Dosage form |
0.5 ~ 20 mg/kg Intraperitoneal administration |
|
Applications |
Retigabine exhibited an additive effect when administered in combination with classical anticonvulsants, most notably diazepam, phenobarbital, phenytoin as well as valproate. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia, 2012, 53(3): 412-424. 2. Stas JI, Bocksteins E, Jensen CS, et al. The anticonvulsant retigabine suppresses neuronal KV2-mediated currents. Scientific Reports, 2016, 6: 35080. 3. De Sarro G, Di Paola ED, Conte G, et al. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363(3): 330-336. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
